Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China

CAMBRIDGE, Mass. and SHANGHAI and SAN FRANCISCO: CAMBRIDGE, Mass. and SHANGHAI and SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for...

Click to view original post